Top

Published in:

01-01-2012 | Original article

Clinical trial of cisplatin-conjugated gelatin microspheres for patients with hepatocellular carcinoma

Authors: Tetsuya Toyama, Norihisa Nitta, Shinichi Ohta, Toyohiko Tanaka, Yukihiro Nagatani, Masashi Takahashi, Kiyoshi Murata, Hisanori Shiomi, Shigeyuki Naka, Yoshimasa Kurumi, Tohru Tani, Yasuhiko Tabata

Published in: Japanese Journal of Radiology | Issue 1/2012

Abstract

Purpose

We report our initial experience with the transarterial chemoembolization (TACE) of unresectable hepatocellular carcinoma (HCC) using cisplatin-conjugated gelatin microspheres (Cis-GMS).

Methods and material

Nineteen patients with 25 HCC nodules (mean diameter 23.0 mm) were treated by selective TACE using 50- to 100-μm Cis-GMS. Tumor necrosis and postembolization syndrome were assessed during the follow-up. The tumor response was evaluated on contrast-enhanced computed tomography images at 1 and 3 months after TACE using Cis-GMS.

Results

All procedures were technically successful in all patients; following the TACE using Cis-GMS, there were no major complications, and postembolization syndrome was minimal. At the 1-month follow-up, the response rate was 12 of the 25 (48%) and 21 of the 25 (84%) HCC nodules based on RECIST 1.1 and EASL criteria, respectively; at the 3-month follow-up, it was 10 of the 25 (40%) and 14 of the 25 (56%) HCC nodules, respectively.

Conclusion

Our initial experience with using Cis-GMS for TACE suggests that these drugs may represent an optimal treatment option for the treatment of advanced HCC and that the use of gelatin microspheres loaded with chemotherapeutic agents warrants further study.

Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153–6.PubMedCrossRef

El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752–63.PubMedCrossRef

Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.PubMedCrossRef

Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25:181–200.PubMedCrossRef

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.PubMedCrossRef

Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–42.PubMedCrossRef

Gunven P. Liver embolizations in oncology: a review. Part I. Arterial (chemo)embolizations. Med Oncol. 2008;25:1–11.PubMedCrossRef

Brown DB, Pilgram TK, Darcy MD, Fundakowski CE, Lisker-Melman M, Chapman WC, et al. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J Vasc Interv Radiol. 2005;16:1661–6.PubMedCrossRef

Grosso M, Vignali C, Quaretti P, Nicolini A, Melchiorre F, Gallarato G, et al. Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. Cardiovasc Intervent Radiol. 2008;31:1141–9.PubMedCrossRef

10.

Malagari K, Alexopoulou E, Chatzimichail K, Hall B, Koskinas J, Ryan S, et al. Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead. Abdom Imaging. 2008;33:512–9.PubMedCrossRef

11.

Konishi M, Tabata Y, Kariya M, Hosseinkhani H, Suzuki A, Fukuhara K, et al. In vivo anti-tumor effect of dual release of cisplatin and adriamycin from biodegradable gelatin hydrogel. J Control Release. 2005;103:7–19.PubMedCrossRef

12.

Konishi M, Tabata Y, Kariya M, Suzuki A, Mandai M, Nanbu K, et al. In vivo anti-tumor effect through the controlled release of cisplatin from biodegradable gelatin hydrogel. J Control Release. 2003;92:301–13.PubMedCrossRef

13.

Ohta S, Nitta N, Sonoda A, Seko A, Tanaka T, Takahashi M, et al. Cisplatin-conjugated degradable gelatin microspheres: fundamental study in vitro. Br J Radiol. 2009;82:380–5.PubMedCrossRef

14.

Nitta N, Ohta S, Tanaka T, Takazakura R, Toyama T, Sonoda A, et al. An initial clinical study on the efficacy of cisplatin-releasing gelatin microspheres for metastatic liver tumors. Eur J Radiol. 2009;71:519–26.PubMedCrossRef

15.

Ohta S, Nitta N, Sonoda A, Seko A, Tanaka T, Takahashi M, et al. Prolonged local persistence of cisplatin-loaded gelatin microspheres and their chemoembolic anti-cancer effect in rabbits. Eur J Radiol. 2009;72:534–40.PubMedCrossRef

16.

Tabata Y, Hijikata S, Muniruzzaman M, Ikada Y. Neovascularization effect of biodegradable gelatin microspheres incorporating basic fibroblast growth factor. J Biomater Sci Polym Ed. 1999;10:79–94.PubMedCrossRef

17.

Tabata Y, Uno K, Ikada Y, Muramatsu S. Potentiation of antitumor activity of macrophages by recombinant interferon alpha A/D contained in gelatin microspheres. Jpn J Cancer Res. 1988;79:636–46.PubMedCrossRef

18.

Hong L, Miyamoto S, Hashimoto N, Tabata Y. Synergistic effect of gelatin microspheres incorporating TGF-beta1 and a physical barrier for fibrous tissue infiltration on skull bone formation. J Biomater Sci Polym Ed. 2000;11:1357–69.PubMedCrossRef

19.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRef

20.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.PubMedCrossRef

21.

Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the study of the liver. J Hepatol. 2001;35:421–30.PubMedCrossRef

22.

Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–81.PubMedCrossRef

23.

Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–9.PubMedCrossRef

24.

Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–71.PubMedCrossRef

25.

Ozeki M, Tabata Y. In vivo degradability of hydrogels prepared from different gelatins by various cross-linking methods. J Biomater Sci Polym Ed. 2005;16:549–56.PubMedCrossRef

26.

Ono Y, Yoshimasu T, Ashikaga R, Inoue M, Shindou H, Fuji K, et al. Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol. 2000;23:564–8.PubMedCrossRef

Title: Clinical trial of cisplatin-conjugated gelatin microspheres for patients with hepatocellular carcinoma
Authors: Tetsuya Toyama
Norihisa Nitta
Shinichi Ohta
Toyohiko Tanaka
Yukihiro Nagatani
Masashi Takahashi
Kiyoshi Murata
Hisanori Shiomi
Shigeyuki Naka
Yoshimasa Kurumi
Tohru Tani
Yasuhiko Tabata
Publication date: 01-01-2012
Publisher: Springer Japan
Published in: Japanese Journal of Radiology / Issue 1/2012
Print ISSN: 1867-1071
Electronic ISSN: 1867-108X
DOI: https://doi.org/10.1007/s11604-011-0010-2

At a glance: The STEP trials

Springer Medicine

Clinical trial of cisplatin-conjugated gelatin microspheres for patients with hepatocellular carcinoma

Abstract

Purpose

Methods and material

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods and material

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2012

Usefulness of portography and contrast-enhanced computed tomography to predict the embolized area in percutaneous transhepatic portal vein embolization with absolute ethanol under temporary balloon occlusion

CT fluoroscopy-guided radiofrequency ablation of osteoid osteoma with double nidi

Precision of the measurement of CT numbers: comparison of dual-energy CT spectral imaging with fast kVp switching and conventional CT with phantoms

Long-term assessment of contrast effects of gadofluorine M and gadofluorine P in magnetic resonance imaging of mice

Chondromyxoid fibroma of the rib with prominent exophytic configuration

Arterial blood supply to the caudate lobe of the liver from the proximal branches of the right inferior phrenic artery in patients with recurrent hepatocellular carcinoma after chemoembolization